DelveInsight’s “Atopic Dermatitis – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Atopic Dermatitis, historical and forecasted epidemiology as well as the Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Atopic Dermatitis Overview
Atopic Dermatitis, or atopic eczema, is a type of skin inflammation (dermatitis). It results in itchy, red, swollen, and cracked skin. Clear fluid may come from the affected areas, often thickening over time. While the condition may occur at any age, it typically starts in childhood with changing severity over the years. In children under one year of age, much of the body may be affected. As children age, the back of the knees and the front of the elbows are the most common areas affected. In adults, the hands and feet are the most commonly affected areas. Scratching worsens symptoms, and affected people have an increased risk of skin infections. Many people with atopic dermatitis develop hay fever or asthma. The word “atopic” indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. The unknown cause involves genetics, immune system dysfunction, environmental exposures, and skin permeability difficulties. If one identical twin is affected, there is an 85% chance the other also has the condition. Those who live in cities and dry climates are more commonly affected. Exposure to certain chemicals or frequent hand washing makes symptoms worse. While emotional stress may make the symptoms worse. The disorder is not contagious. The diagnosis is typically based on the signs and symptoms.
Atopic Dermatitis Epidemiology Insights
As per the National Eczema Association 2019, Atopic dermatitis (AD) is the most common type of eczema. In fact, more than 18 million American adults have atopic dermatitis, which often appears as a red, itchy rash normally on the cheeks, arms, and legs.
A disease burden study was conducted by Eckert et al. (2019) on European adult patients with Atopic Dermatitis, and the data was collected from the 2016 National Health and Wellness Survey conducted in France, Germany, Italy, Spain, and the United Kingdom. Most respondents, with or without a diagnosis of Atopic Dermatitis, were from Spain (37.0%), followed by Italy (24.6%), France (19.0%), Germany (10.6%), and the United Kingdom (8.9%). Most patients (69.3%) were women, and their mean age was 44 years.
Click here to learn more about the Atopic Dermatitis Market Landscape
The Report Covers the Atopic Dermatitis Epidemiology Segmented by:
Atopic Dermatitis prevalent cases
Atopic Dermatitis diagnosed prevalent cases
Atopic Dermatitis severity-specific distribution
Atopic Dermatitis gender-specific prevalent cases
Atopic Dermatitis Market Outlook
The treatment of Atopic Dermatitis aims to reduce the duration, severity, and frequency of disease exacerbations. It is implemented step-wise according to disease severity (mild, moderate, or severe). Off-label treatment, especially systemic immunosuppressants and systemic (oral and injectable) corticosteroids, are frequently prescribed for patients unresponsive to topical therapy. Systemic corticosteroids are indicated for short-term treatment of acute severe Atopic Dermatitis.
Optimal Atopic Dermatitis management includes topical corticosteroids (TCs) as the first-line treatment for Atopic Dermatitis flare-ups. The potencies of these topical corticosteroids range from group I, which is most potent (e.g., clobetasol [Temovate]), through group VII, which is least potent (e.g., hydrocortisone 1%). However, TCS has various side effects and is not recommended for long-term use. The principal complication of prolonged application of topical corticosteroids, especially those of higher potency, is skin atrophy. Other local complications include telangiectasia, striae, hypopigmentation, and corticosteroid acne.
Key Companies Working in the Atopic Dermatitis Market
Sanofi
Regeneron Pharmaceuticals
Pfizer
Japan Tobacco and Torii Pharmaceutical
Eli Lilly and Company
AbbVie
LEO Pharma
Incyte Corporation
Arena Pharmaceuticals
And many others
Atopic Dermatitis Therapies Covered and Analyzed in the Report:
Dupixent
Eucrisa
Olumiant
Corectim Ointment
Rinvoq
Cibinqo
Adtralza
Opzelura
Learn more about the Key Companies and Emerging Therapies in the Atopic Dermatitis Market.
Table of Contents
Key Insights
Atopic Dermatitis Introduction
Executive Summary of Atopic Dermatitis
Disease Background and Overview
Epidemiology and patient population
Atopic Dermatitis Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Atopic Dermatitis Market Outlook.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services